shutterstock_1014176104_willy_barton

Willy Barton / Shutterstock.com

16 June 2020Big PharmaRory O'Neill

UKIPO cancels SPC extension at owner’s request

The UK Intellectual Property Office has agreed to revoke an extension to a supplementary protection certificate (SPC) for immunosuppressant tocilizumab, at the request of the owners.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Unitary SPC should follow new patent system: EC official

11 June 2020 The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.

Royalty Pharma: welcome clarity mixed with unwelcome ambiguity

15 May 2020 The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.

More on this story

Unitary SPC should follow new patent system: EC official

11 June 2020 The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.

Royalty Pharma: welcome clarity mixed with unwelcome ambiguity

15 May 2020 The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.

More on this story

Unitary SPC should follow new patent system: EC official

11 June 2020 The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.

Royalty Pharma: welcome clarity mixed with unwelcome ambiguity

15 May 2020 The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.

More features

President Trump 2.0: Five major areas to watch

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?

Pfizer infringed haemophilia therapy patent, says court